Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
Lead Product(s): Dexamethasone
Therapeutic Area: Immunology Product Name: Zeqmelit
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kamada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022